Omnicell Stock Price, News & Analysis (NASDAQ:OMCL)

$44.20 0.00 (0.00 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$44.20
Today's Range$44.15 - $44.75
52-Week Range$36.65 - $55.40
Volume251,990 shs
Average Volume419,457 shs
Market Capitalization$1.68 billion
P/E Ratio86.67
Dividend YieldN/A
Beta0.65

About Omnicell (NASDAQ:OMCL)

Omnicell logoOmnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Software & Technology Services
Sub-IndustryHealth Care Technology
SectorMedical
SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100

Debt

Debt-to-Equity Ratio0.38%
Current Ratio1.73%
Quick Ratio1.28%

Price-To-Earnings

Trailing P/E Ratio86.6683660463931
Forward P/E Ratio57.40
P/E Growth3.64

Sales & Book Value

Annual Sales$716.16 million
Price / Sales2.34
Cash Flow$1.59 per share
Price / Cash27.80
Book Value$13.64 per share
Price / Book3.24

Profitability

Trailing EPS$0.51
Net Income$20.60 million
Net Margins2.88%
Return on Equity1.54%
Return on Assets0.77%

Miscellaneous

Employees2,444
Outstanding Shares37,930,000

Omnicell (NASDAQ:OMCL) Frequently Asked Questions

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its quarterly earnings results on Thursday, February, 1st. The company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.52 by $0.02. The business had revenue of $198.26 million for the quarter, compared to the consensus estimate of $205.50 million. Omnicell had a return on equity of 1.54% and a net margin of 2.88%. The firm's revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.37 EPS. View Omnicell's Earnings History.

When will Omnicell make its next earnings announcement?

Omnicell is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Omnicell.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of $1.85-2.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.98. The company issued revenue guidance of $780-800 million, compared to the consensus revenue estimate of $809.67 million.Omnicell also updated its Q1 guidance to $0.22-0.28 EPS.

Where is Omnicell's stock going? Where will Omnicell's stock price be in 2018?

7 Wall Street analysts have issued 12 month price targets for Omnicell's shares. Their forecasts range from $44.00 to $67.00. On average, they expect Omnicell's stock price to reach $56.14 in the next twelve months. View Analyst Ratings for Omnicell.

What are Wall Street analysts saying about Omnicell stock?

Here are some recent quotes from research analysts about Omnicell stock:

  • 1. According to Zacks Investment Research, "Omnicell’s fourth-quarter 2017 performance was impressive with year-over-year increase in both earnings and revenues. Further, both of the company’s segments witnessed year-over-year growth. We are encouraged to note that the company is working on product innovation through R&D. The company is expected to gain from its recent launches and strategic partnerships. Its recent product launches include the XR2 Automated Central Pharmacy System and the IVX Workflow, IVX Workflow creates a significant technological advancement for sterile compounding workflow processes, enabling pharmacies to safely and efficiently compound and prepare IV doses.Also, improvement in margin is also encouraging. However, a tough competitive landscape acts as a dampener. Over the past month, Omnicell’s shares have been trading below the broader industry." (2/2/2018)
  • 2. Cantor Fitzgerald analysts commented, "Timing issues snag 4Q17 revenue again. Revenue of $198 million (+15.1% y/y) was below our estimate of $205 million. Revenue was negatively affected by delayed implementation at two large accounts. Similar to 3Q17, we believe these issues are timing related and not worrisome. It appears as though the XT rollout is going well with 95% of frame revenue related to XT. This was in line with management’s expectations. While revenue was below our estimations, non-GAAP EPS of $0.54 was above our estimate of $0.51. Notably, GAAP gross margin exceeded our estimate by more than 200bps. Adjusted operating margin was 14.2% compared to 11.7% in 3Q17 and 10.7% a year ago. The company is clearly seeing the benefits as XT implementations scale." (2/1/2018)

Who are some of Omnicell's key competitors?

Who are Omnicell's key executives?

Omnicell's management team includes the folowing people:

  • Randall A. Lipps, Chairman of the Board, President, Chief Executive Officer (Age 59)
  • Peter J. Kuipers, Chief Financial Officer, Executive Vice President (Age 45)
  • Daniel S. Johnston, Executive Vice President, Chief Legal and Administrative Officer (Age 53)
  • J. Christopher Drew, Executive Vice President of Sales and Marketing for North American Automation (Age 51)
  • Nhat H. Ngo, Executive Vice President - Strategy and Business Development (Age 44)
  • Robin Gene Seim, Executive Vice President, Global Automation and Medication Adherence (Age 57)
  • Jorge R. Taborga, Executive Vice President - Engineering and Integration Management Office (Age 57)
  • Joseph B. Spears, Principal Chief Accounting Officer (Age 58)
  • James T. Judson, Lead Independent Director (Age 62)
  • Joanne B. Bauer, Independent Director (Age 61)

Who owns Omnicell stock?

Omnicell's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.76%), Conestoga Capital Advisors LLC (4.73%), Champlain Investment Partners LLC (3.85%), Eagle Asset Management Inc. (3.60%), Bank of New York Mellon Corp (2.70%) and Carillon Tower Advisers Inc. (2.10%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.

Who sold Omnicell stock? Who is selling Omnicell stock?

Omnicell's stock was sold by a variety of institutional investors in the last quarter, including Martingale Asset Management L P, Bank of New York Mellon Corp, Raymond James & Associates, Foundry Partners LLC, UBS Asset Management Americas Inc., Segall Bryant & Hamill LLC, Wells Fargo & Company MN and Rice Hall James & Associates LLC. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.

Who bought Omnicell stock? Who is buying Omnicell stock?

Omnicell's stock was purchased by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Eagle Asset Management Inc., Kennedy Capital Management Inc., Braun Stacey Associates Inc., BlackRock Inc., Conestoga Capital Advisors LLC, Westwood Holdings Group Inc. and Deutsche Bank AG. View Insider Buying and Selling for Omnicell.

How do I buy Omnicell stock?

Shares of Omnicell can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omnicell's stock price today?

One share of Omnicell stock can currently be purchased for approximately $44.20.

How big of a company is Omnicell?

Omnicell has a market capitalization of $1.68 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.51 on an earnings per share basis. Omnicell employs 2,444 workers across the globe.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]


MarketBeat Community Rating for Omnicell (OMCL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  461
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Omnicell (NASDAQ:OMCL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.862.862.75
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $56.14$55.14$54.86$49.00
Price Target Upside: 24.07% upside7.81% upside7.99% upside0.93% upside

Omnicell (NASDAQ:OMCL) Consensus Price Target History

Price Target History for Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ:OMCL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2018Piper Jaffray CompaniesBoost Price TargetNeutral -> Neutral$38.00 -> $44.00HighView Rating Details
2/2/2018Craig HallumDowngradeBuy -> HoldHighView Rating Details
2/1/2018Cantor FitzgeraldReiterated RatingBuy$63.00HighView Rating Details
1/29/2018OppenheimerReiterated RatingBuy$55.00MediumView Rating Details
9/5/2017BenchmarkBoost Price TargetBuy -> Buy$55.00 -> $67.00MediumView Rating Details
7/28/2017Dougherty & CoBoost Price TargetBuy$45.00 -> $49.00HighView Rating Details
4/26/2017CIBCBoost Price TargetOutperform$43.00 -> $53.00LowView Rating Details
9/8/2016SidotiDowngradeBuy -> Neutral$43.00N/AView Rating Details
7/29/2016FBR & CoBoost Price TargetOutperform$40.00 -> $41.00N/AView Rating Details
3/21/2016Topeka Capital MarketsLower Price TargetBuy$38.00 -> $37.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Omnicell (NASDAQ:OMCL) Earnings History and Estimates Chart

Earnings by Quarter for Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ OMCL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$0.37N/AView Earnings Details
2/1/2018Q4 2017$0.52$0.54$205.50 million$198.26 millionViewListenView Earnings Details
10/26/2017Q3 2017$0.42$0.42$192.45 million$186.78 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.02$0.02$174.08 million$180.90 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.30)$0.06$152.63 million$150.90 millionViewListenView Earnings Details
2/15/2017Q4 2016$0.41$0.37$179.28 million$171.97 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.40$179.75 million$179.40 millionViewListenView Earnings Details
7/28/2016Q216$0.32$0.38$170.89 million$175.60 millionViewListenView Earnings Details
4/28/2016Q116$0.26$0.35$167.18 million$171.00 millionViewListenView Earnings Details
2/4/2016Q415$0.39$0.40$126.89 million$130.30 millionViewListenView Earnings Details
10/29/2015Q315$0.36$0.36$128.50 million$125.20 millionViewListenView Earnings Details
7/30/2015Q215$0.32$0.28$121.35 million$112.80 millionViewListenView Earnings Details
4/30/2015Q115$0.23$0.29$112.00 million$16.20 millionViewN/AView Earnings Details
2/3/2015Q414$0.33$0.39$114.65 million$121.50 millionViewListenView Earnings Details
10/30/2014Q314$0.31$0.30$106.10 million$112.50 millionViewListenView Earnings Details
7/31/2014Q214$0.29$0.30$103.23 million$105.10 millionViewListenView Earnings Details
5/1/2014Q114$0.24$0.26$97.49 million$101.80 millionViewListenView Earnings Details
2/4/2014Q413$0.28$0.29$101.13 million$105.80 millionViewListenView Earnings Details
10/31/2013Q313$0.28$0.31$94.96 million$94.03 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.25$0.27$92.42 million$93.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.19$0.21$87.20 million$87.11 millionViewN/AView Earnings Details
1/31/2013Q4 2012$0.25$0.25$87.31 million$90.16 millionViewN/AView Earnings Details
10/25/2012$0.22$0.29ViewN/AView Earnings Details
8/1/2012$0.18$0.20ViewN/AView Earnings Details
5/2/2012$0.13$0.13ViewN/AView Earnings Details
1/26/2012$0.16$0.19ViewN/AView Earnings Details
10/27/2011$0.16$0.16ViewN/AView Earnings Details
7/28/2011$0.13$0.15ViewN/AView Earnings Details
5/2/2011$0.10$0.11ViewN/AView Earnings Details
1/27/2011$0.12$0.11ViewN/AView Earnings Details
10/27/2010Q3 2010$0.02$0.02ViewN/AView Earnings Details
7/22/2010Q2 2010$0.04$0.06ViewN/AView Earnings Details
4/26/2010Q1 2010$0.02$0.03ViewN/AView Earnings Details
1/28/2010Q4 2009$0.03$0.02ViewN/AView Earnings Details
10/22/2009Q3 2009$0.02$0.03ViewN/AView Earnings Details
7/23/2009Q2 2009$0.01$0.03ViewN/AView Earnings Details
4/30/2009Q1 2009($0.02)($0.01)ViewN/AView Earnings Details
1/29/2009Q4 2008$0.07$0.10ViewN/AView Earnings Details
10/23/2008Q3 2008$0.09$0.09ViewN/AView Earnings Details
7/21/2008Q2 2008$0.08$0.09ViewN/AView Earnings Details
4/21/2008Q1 2008$0.11$0.11ViewN/AView Earnings Details
1/31/2008Q4 2007$0.20$0.21ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Omnicell (NASDAQ:OMCL) Earnings Estimates

Current Year EPS Consensus Estimate: $0.77 EPS
Next Year EPS Consensus Estimate: $1.15 EPS

Dividends

Dividend History for Omnicell (NASDAQ:OMCL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Omnicell (NASDAQ OMCL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.77%
Insider Trades by Quarter for Omnicell (NASDAQ:OMCL)
Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ OMCL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017Peter J KuipersCFOSell1,926$51.69$99,554.9440,544View SEC Filing  
11/17/2017Dan S JohnstonEVPSell14,613$47.81$698,647.5343,621View SEC Filing  
11/17/2017Peter J KuipersVPSell4,724$47.74$225,523.7640,544View SEC Filing  
11/6/2017Jorge R TaborgaVPSell6,295$48.69$306,503.5550,013View SEC Filing  
10/2/2017Peter J KuipersVPSell3,532$50.96$179,990.7240,714View SEC Filing  
9/15/2017Robin Gene SeimEVPSell9,780$48.97$478,926.6055,896View SEC Filing  
9/5/2017Gary S. PetersmeyerDirectorSell1,000$51.73$51,730.00View SEC Filing  
9/1/2017Randall A. LippsChairmanSell10,625$52.00$552,500.00View SEC Filing  
8/18/2017Dan S JohnstonEVPSell16,400$48.86$801,304.0051,621View SEC Filing  
8/15/2017Robin Gene SeimEVPSell15,109$50.86$768,443.7458,144View SEC Filing  
8/9/2017Peter J KuipersVPSell18,054$50.31$908,296.7444,236View SEC Filing  
8/8/2017J Christopher DrewVPSell11,375$51.16$581,945.00139,201View SEC Filing  
8/7/2017Jorge R TaborgaVPSell20,719$50.98$1,056,254.6253,270View SEC Filing  
8/1/2017Randall A LippsChairmanSell40,000$49.76$1,990,400.00196,551View SEC Filing  
7/28/2017Randall A LippsChairmanSell37,500$46.00$1,725,000.00196,551View SEC Filing  
6/19/2017Randall A LippsChairmanSell31,527$42.87$1,351,562.49196,551View SEC Filing  
6/5/2017Randall A LippsChairmanSell9,900$43.00$425,700.00208,982View SEC Filing  
5/26/2017James T JudsonDirectorSell12,148$41.50$504,142.0019,130View SEC Filing  
5/25/2017Gary S PetersmeyerDirectorSell2,200$41.41$91,102.0021,075View SEC Filing  
5/19/2017Dan S JohnstonEVPSell16,400$40.67$666,988.0061,696View SEC Filing  
5/9/2017J Christopher DrewVPSell10,625$40.97$435,306.25152,057View SEC Filing  
4/25/2017Randall A LippsChairmanSell18,200$41.00$746,200.00208,982View SEC Filing  
3/10/2017Gary S PetersmeyerDirectorSell2,658$37.45$99,542.1020,085View SEC Filing  
2/21/2017Sara J WhiteDirectorSell3,443$38.06$131,040.5843,214View SEC Filing  
11/18/2016Dan S JohnstonEVPSell8,850$33.65$297,802.5058,877View SEC Filing  
11/18/2016Jorge R TaborgaVPSell2,068$33.66$69,608.8847,223View SEC Filing  
11/8/2016J Christopher DrewVPSell20,000$31.95$639,000.00139,844View SEC Filing  
9/12/2016Gary S PetersmeyerDirectorSell2,000$37.98$75,960.0017,987View SEC Filing  
9/8/2016Gary S PetersmeyerDirectorSell2,400$39.39$94,536.0017,987View SEC Filing  
9/6/2016Gary S PetersmeyerDirectorSell2,000$39.02$78,040.0019,987View SEC Filing  
9/2/2016Gary S PetersmeyerDirectorSell3,000$38.52$115,560.0019,987View SEC Filing  
8/19/2016Dan S JohnstonEVPSell8,850$36.93$326,830.5064,877View SEC Filing  
8/19/2016Jorge R TaborgaVPSell1,778$36.92$65,643.7649,073View SEC Filing  
8/11/2016Randall A LippsChairmanSell37,425$37.37$1,398,572.25192,325View SEC Filing  
8/9/2016J Christopher DrewVPSell15,000$37.89$568,350.00139,844View SEC Filing  
8/9/2016James T JudsonDirectorSell6,250$37.98$237,375.0015,300View SEC Filing  
8/4/2016Gary S PetersmeyerDirectorSell8,750$37.84$331,100.0019,987View SEC Filing  
7/29/2016Jorge R TaborgaVPSell10,023$40.00$400,920.0049,073View SEC Filing  
7/6/2016Robin Gene SeimEVPSell5,302$34.75$184,244.5055,420View SEC Filing  
7/1/2016Robin Gene SeimEVPSell3,645$35.00$127,575.0055,420View SEC Filing  
6/6/2016Jorge R TaborgaVPSell25,979$33.00$857,307.0050,734View SEC Filing  
5/24/2016Gary S PetersmeyerDirectorSell6,250$31.22$195,125.0015,557View SEC Filing  
5/20/2016Dan S JohnstonEVPSell8,850$30.73$271,960.5073,105View SEC Filing  
5/20/2016Jorge R TaborgaVPSell1,933$30.73$59,401.0952,667View SEC Filing  
5/10/2016J Christopher DrewVPSell15,000$31.63$474,450.00144,573View SEC Filing  
5/5/2016Sara J WhiteDirectorSell2,000$31.76$63,520.0040,433View SEC Filing  
4/29/2016Robin Gene SeimEVPSell6,407$31.00$198,617.0059,619View SEC Filing  
4/26/2016Jorge R TaborgaVPSell23,827$30.00$714,810.0052,667View SEC Filing  
4/26/2016Robin Gene SeimEVPSell767$30.00$23,010.0060,386View SEC Filing  
2/19/2016Dan S JohnstonEVPSell8,850$27.41$242,578.5079,716View SEC Filing  
2/19/2016Jorge R TaborgaVPSell1,685$27.42$46,202.7054,806View SEC Filing  
2/11/2016Randall A. LippsCEOSell40,000$27.81$1,112,400.00204,705View SEC Filing  
2/9/2016J Christopher DrewVPSell15,000$27.57$413,550.00145,355View SEC Filing  
12/18/2015Nhat H. NgoVPSell4,069$28.71$116,820.9923,431View SEC Filing  
11/17/2015Dan S. JohnstonVPSell2,500$28.00$70,000.0066,393View SEC Filing  
11/10/2015J Christopher DrewVPSell25,000$26.79$669,750.00137,180View SEC Filing  
11/9/2015Dan S. JohnstonVPSell2,700$27.29$73,683.0066,393View SEC Filing  
10/13/2015Gary S. PetersmeyerDirectorSell670$31.66$21,212.2015,557View SEC Filing  
8/13/2015Robin Gene SeimCFOSell23,946$35.63$853,195.98View SEC Filing  
7/1/2015Robin Gene SeimCFOSell19,582$37.84$740,982.88View SEC Filing  
6/17/2015Nhat H NgoVPSell4,067$38.78$157,718.26View SEC Filing  
6/2/2015James T JudsonDirectorSell8,032$36.83$295,818.56View SEC Filing  
6/2/2015Nhat H NgoVPSell6,375$36.80$234,600.00View SEC Filing  
5/26/2015Sara J WhiteDirectorSell4,000$36.25$145,000.00View SEC Filing  
5/7/2015Dan S JohnstonVPSell7,715$34.25$264,238.75View SEC Filing  
2/12/2015J Christopher DrewVPSell25,000$34.62$865,500.00View SEC Filing  
2/6/2015Dan S JohnstonVPSell6,552$33.29$218,116.08View SEC Filing  
2/2/2015James T JudsonDirectorSell5,000$31.61$158,050.00View SEC Filing  
1/13/2015Gary S PetersmeyerDirectorSell670$31.31$20,977.70View SEC Filing  
1/2/2015James T JudsonDirectorSell5,000$32.36$161,800.00View SEC Filing  
1/2/2015Robin Gene SeimCFOSell1,948$32.36$63,037.28View SEC Filing  
12/17/2014Marga Ortigas-WedekindVPSell4,080$32.20$131,376.00View SEC Filing  
12/15/2014Gary S PetersmeyerDirectorSell670$33.25$22,277.50View SEC Filing  
12/8/2014Nhat H NgoVPSell1,754$32.89$57,689.06View SEC Filing  
12/1/2014James T JudsonDirectorSell5,000$31.94$159,700.00View SEC Filing  
11/12/2014Randy D LindholmDirectorSell5,000$31.72$158,600.00View SEC Filing  
11/11/2014J Christopher DrewVPSell37,500$31.86$1,194,750.00View SEC Filing  
11/7/2014Dan S JohnstonVPSell27,625$31.74$876,817.50View SEC Filing  
11/3/2014James T JudsonDirectorSell5,000$32.27$161,350.00View SEC Filing  
10/3/2014Nhat H NgoVPSell2,275$28.00$63,700.00View SEC Filing  
10/1/2014James T JudsonDirectorSell5,000$27.02$135,100.00View SEC Filing  
9/15/2014Jorge R TaborgaVPSell944$26.37$24,893.28View SEC Filing  
9/15/2014Robin Gene SeimCFOSell9,347$26.32$246,013.04View SEC Filing  
9/2/2014James T JudsonDirectorSell5,000$28.18$140,900.00View SEC Filing  
9/2/2014Robin Gene SeimCFOSell27,500$28.19$775,225.00View SEC Filing  
8/26/2014Dan S JohnstonVPSell6,250$28.00$175,000.00View SEC Filing  
8/26/2014James T JudsonDirectorSell9,913$27.91$276,671.83View SEC Filing  
7/9/2014Robin Gene SeimCFOSell2,442$28.21$68,888.82View SEC Filing  
7/1/2014James T JudsonDirectorSell5,000$29.28$146,400.00View SEC Filing  
6/26/2014Marga Ortigas-WedekindVPSell2,961$28.17$83,411.37View SEC Filing  
6/25/2014Nhat H NgoVPSell2,274$28.00$63,672.00View SEC Filing  
6/17/2014Nhat H NgoVPSell1,420$27.70$39,334.00View SEC Filing  
6/10/2014Nhat H NgoVPSell1,964$26.38$51,810.32View SEC Filing  
6/2/2014Gary S PetersmeyerDirectorSell5,000$26.45$132,250.00View SEC Filing  
5/21/2014Gary PetersmeyerDirectorSell2,000$26.51$53,020.0017,088View SEC Filing  
5/13/2014J Christopher DrewVPSell37,500$26.08$978,000.00151,448View SEC Filing  
5/7/2014Dan JohnstonVPSell4,000$25.25$101,000.0075,558View SEC Filing  
5/1/2014James JudsonDirectorSell5,000$26.24$131,200.0017,945View SEC Filing  
4/8/2014Nhat NgoVPSell1,002$27.40$27,454.8052,896View SEC Filing  
3/18/2014Marga Ortigas-WedekindVPSell5,880$30.00$176,400.0053,445View SEC Filing  
3/18/2014Randall LippsCEOSell124,910$29.89$3,733,559.90220,997View SEC Filing  
12/18/2013Nhat NgoVPSell1,462$24.43$35,716.6645,585View SEC Filing  
12/18/2013Randall LippsCEOSell64,739$24.30$1,573,157.70186,048View SEC Filing  
12/3/2013Dan JohnstonVPSell73,419$23.24$1,706,257.5674,885View SEC Filing  
11/11/2013Randy LindholmDirectorSell3,587$23.00$82,501.0026,917View SEC Filing  
11/7/2013Dan JohnstonVPSell8,000$22.99$183,920.0074,885View SEC Filing  
10/23/2013Robin Gene SeimCFOSell7,664$24.50$187,768.00View SEC Filing  
10/21/2013Robin Gene SeimCFOSell9,349$23.76$222,132.24View SEC Filing  
10/1/2013James T JudsonDirectorSell5,000$23.66$118,300.00View SEC Filing  
9/24/2013Randall LippsCEOSell68,204$25.00$1,705,100.00202,362View SEC Filing  
9/23/2013Marga Ortigas-WedekindVPSell4,000$25.00$100,000.0080,903View SEC Filing  
9/23/2013Randall LippsCEOSell5,083$25.00$127,075.00202,362View SEC Filing  
9/20/2013Robin Gene SeimCFOSell27,500$24.35$669,625.0069,700View SEC Filing  
9/18/2013Randall LippsCEOSell64,453$23.67$1,525,602.51202,362View SEC Filing  
9/4/2013Nhat H NgoVPSell7,362$24.00$176,688.00View SEC Filing  
9/3/2013James JudsonDirectorSell5,000$22.77$113,850.0017,945View SEC Filing  
8/20/2013James JudsonDirectorSell11,724$22.74$266,603.7617,945View SEC Filing  
8/13/2013J Christopher DrewVPSell20,000$22.83$456,600.00131,221View SEC Filing  
8/12/2013Donald WegmillerDirectorSell34,976$22.87$799,901.128,002View SEC Filing  
8/7/2013Dan JohnstonVPSell8,000$22.92$183,360.0074,885View SEC Filing  
8/6/2013Randall LippsCEOSell5,321$23.00$122,383.00211,905View SEC Filing  
8/2/2013Randall A LippsCEOSell25,000$22.50$562,500.00View SEC Filing  
8/1/2013James JudsonDirectorSell5,000$21.00$105,000.0029,669View SEC Filing  
7/19/2013Nhat H NgoVPSell41,875$21.00$879,375.00View SEC Filing  
7/19/2013Randall A LippsCEOSell5,080$21.00$106,680.00View SEC Filing  
7/1/2013James T JudsonDirectorSell5,000$20.46$102,300.00View SEC Filing  
7/1/2013Robin Gene SeimCFOSell13,032$20.42$266,113.44View SEC Filing  
6/28/2013Marga Ortigas-WedekindVPSell4,545$20.00$90,900.00View SEC Filing  
6/28/2013Randall A LippsCEOSell25,000$20.00$500,000.00View SEC Filing  
6/21/2013Nhat H NgoVPSell3,459$19.01$65,755.59View SEC Filing  
6/18/2013Randall A LippsCEOSell66,378$19.10$1,267,819.80View SEC Filing  
6/10/2013Randy D LindholmDirectorSell23,901$19.14$457,465.14View SEC Filing  
6/4/2013Robin Gene SeimCFOSell25,000$18.72$468,000.00View SEC Filing  
5/22/2013Gary S PetersmeyerDirectorSell2,750$18.10$49,775.00View SEC Filing  
5/16/2013J Christopher DrewVPSell26,000$18.69$485,940.00View SEC Filing  
5/14/2013J Christopher DrewVPSell26,000$18.45$479,700.00View SEC Filing  
5/10/2013Sara J WhiteDirectorSell7,200$18.50$133,200.00View SEC Filing  
5/7/2013Dan S JohnstonVPSell8,000$18.44$147,520.00View SEC Filing  
12/3/2012Gary S PetersmeyerDirectorSell1,359$15.17$20,616.03View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Omnicell (NASDAQ OMCL) News Headlines

Source:
DateHeadline
Commit To Purchase Omnicell At $35, Earn 6.6% Annualized Using OptionsCommit To Purchase Omnicell At $35, Earn 6.6% Annualized Using Options
www.nasdaq.com - February 23 at 4:58 PM
Heres Why You Should Keep Omnicell (OMCL) in Your PortfolioHere's Why You Should Keep Omnicell (OMCL) in Your Portfolio
finance.yahoo.com - February 22 at 4:53 PM
Here's Why You Should Keep Omnicell (OMCL) in Your PortfolioHere's Why You Should Keep Omnicell (OMCL) in Your Portfolio
finance.yahoo.com - February 22 at 4:53 PM
Pomona Valley Hospital Medical Center Adopting In-House IV Compounding with ...Pomona Valley Hospital Medical Center Adopting In-House IV Compounding with ...
www.prnewswire.com - February 16 at 4:38 PM
Pomona Valley Hospital Medical Center Adopting In-House IV Compounding with Omnicells IV RoboticsPomona Valley Hospital Medical Center Adopting In-House IV Compounding with Omnicell's IV Robotics
finance.yahoo.com - February 12 at 9:07 AM
Omnicell, Inc. (OMCL) Expected to Announce Quarterly Sales of $177.37 MillionOmnicell, Inc. (OMCL) Expected to Announce Quarterly Sales of $177.37 Million
www.americanbankingnews.com - February 11 at 8:54 AM
Multiple Hospitals Adopt Omnicells XR2 Automated Central Pharmacy System to Enhance Medication Inventory ManagementMultiple Hospitals Adopt Omnicell's XR2 Automated Central Pharmacy System to Enhance Medication Inventory Management
finance.yahoo.com - February 6 at 4:23 PM
Omnicells Automated Medication Dispensing System Receives Top KLAS Award for the 12th Consecutive YearOmnicell's Automated Medication Dispensing System Receives Top KLAS Award for the 12th Consecutive Year
finance.yahoo.com - February 5 at 9:09 AM
Craig Hallum Downgrades Omnicell (OMCL) to HoldCraig Hallum Downgrades Omnicell (OMCL) to Hold
www.americanbankingnews.com - February 3 at 12:04 AM
Omnicell (OMCL) Given New $44.00 Price Target at Piper Jaffray CompaniesOmnicell (OMCL) Given New $44.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - February 2 at 8:56 PM
Omnicell (OMCL) Upgraded to "Hold" at Zacks Investment ResearchOmnicell (OMCL) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 2 at 4:58 PM
Omnicell tops 4Q profit forecastsOmnicell tops 4Q profit forecasts
finance.yahoo.com - February 2 at 9:11 AM
Omnicell (OMCL) Stock Rating Reaffirmed by Cantor FitzgeraldOmnicell (OMCL) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - February 2 at 12:08 AM
Omnicell (OMCL) Releases  Earnings ResultsOmnicell (OMCL) Releases Earnings Results
www.americanbankingnews.com - February 1 at 9:14 PM
Omnicell (OMCL) Releases Q1 Earnings GuidanceOmnicell (OMCL) Releases Q1 Earnings Guidance
www.americanbankingnews.com - February 1 at 6:14 PM
Omnicell (OMCL) Updates FY18 Earnings GuidanceOmnicell (OMCL) Updates FY18 Earnings Guidance
www.americanbankingnews.com - February 1 at 6:14 PM
Omnicell Reports Results for Fiscal Year and Fourth Quarter 2017Omnicell Reports Results for Fiscal Year and Fourth Quarter 2017
finance.yahoo.com - February 1 at 4:23 PM
Omnicell, Inc. to Host Earnings CallOmnicell, Inc. to Host Earnings Call
finance.yahoo.com - February 1 at 4:23 PM
Interested In Omnicell Inc (NASDAQ:OMCL)? Here’s How It’s PerformingInterested In Omnicell Inc (NASDAQ:OMCL)? Here’s How It’s Performing
finance.yahoo.com - February 1 at 9:17 AM
Omnicell, Inc. (OMCL) Receives Average Recommendation of "Hold" from BrokeragesOmnicell, Inc. (OMCL) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 30 at 1:50 PM
Omnicell (OMCL) Scheduled to Post Quarterly Earnings on ThursdayOmnicell (OMCL) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - January 29 at 8:16 PM
Omnicells (OMCL) Buy Rating Reiterated at OppenheimerOmnicell's (OMCL) Buy Rating Reiterated at Oppenheimer
www.americanbankingnews.com - January 29 at 1:46 PM
Dartmouth-Hitchcock Health Selects Omnicells Performance Center to Help Develop Centralized Pharmacy Service CenterDartmouth-Hitchcock Health Selects Omnicell's Performance Center to Help Develop Centralized Pharmacy Service Center
finance.yahoo.com - January 29 at 9:18 AM
Omnicell to Release Fourth Quarter 2017 Earnings Results on February 1, 2018Omnicell to Release Fourth Quarter 2017 Earnings Results on February 1, 2018
finance.yahoo.com - January 25 at 4:23 PM
Omnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $204.19 MillionOmnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $204.19 Million
www.americanbankingnews.com - January 25 at 5:44 AM
Hospitals Adopt Omnicells IV Compounding Automation to Support Patient Safety and Quality InitiativesHospitals Adopt Omnicell's IV Compounding Automation to Support Patient Safety and Quality Initiatives
finance.yahoo.com - January 24 at 9:40 AM
$0.52 EPS Expected for Omnicell, Inc. (OMCL) This Quarter$0.52 EPS Expected for Omnicell, Inc. (OMCL) This Quarter
www.americanbankingnews.com - January 23 at 3:24 AM
Omnicell (OMCL) Stock Rating Lowered by BidaskClubOmnicell (OMCL) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 21 at 2:16 PM
Head-To-Head Review: Greenway Health (GWAY) and Omnicell (OMCL)Head-To-Head Review: Greenway Health (GWAY) and Omnicell (OMCL)
www.americanbankingnews.com - January 16 at 9:26 PM
Zacks Investment Research Lowers Omnicell (OMCL) to SellZacks Investment Research Lowers Omnicell (OMCL) to Sell
www.americanbankingnews.com - January 10 at 3:52 PM
IBD Rating Upgrades: Omnicell Flashes Improved Price StrengthIBD Rating Upgrades: Omnicell Flashes Improved Price Strength
finance.yahoo.com - January 8 at 10:24 AM
 Brokerages Anticipate Omnicell, Inc. (OMCL) Will Announce Earnings of $0.52 Per Share Brokerages Anticipate Omnicell, Inc. (OMCL) Will Announce Earnings of $0.52 Per Share
www.americanbankingnews.com - January 6 at 1:08 AM
Omnicell, Inc. (OMCL) Given Average Recommendation of "Buy" by AnalystsOmnicell, Inc. (OMCL) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 5 at 11:38 AM
Omnicell (OMCL) Raised to Hold at Zacks Investment ResearchOmnicell (OMCL) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - December 27 at 3:14 PM
Omnicell (OMCL) Downgraded to "Sell" at BidaskClubOmnicell (OMCL) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - December 22 at 7:00 PM
Zacks: Brokerages Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $204.19 MillionZacks: Brokerages Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $204.19 Million
www.americanbankingnews.com - December 22 at 12:50 PM
Zacks: Brokerages Expect Omnicell, Inc. (OMCL) to Announce $0.52 EPSZacks: Brokerages Expect Omnicell, Inc. (OMCL) to Announce $0.52 EPS
www.americanbankingnews.com - December 20 at 3:08 PM
UPMC Chooses Revolutionary Technology from Omnicell to Elevate and Automate PharmacyUPMC Chooses Revolutionary Technology from Omnicell to Elevate and Automate Pharmacy
finance.yahoo.com - December 20 at 10:19 AM
Omnicell, Inc. – Value Analysis (NASDAQ:OMCL) : December 18, 2017Omnicell, Inc. – Value Analysis (NASDAQ:OMCL) : December 18, 2017
finance.yahoo.com - December 19 at 10:18 AM
Insider Selling: Omnicell, Inc. (OMCL) CFO Sells 1,926 Shares of StockInsider Selling: Omnicell, Inc. (OMCL) CFO Sells 1,926 Shares of Stock
www.americanbankingnews.com - December 18 at 6:20 PM
Omnicell, Inc. breached its 50 day moving average in a Bearish Manner : OMCL-US : December 15, 2017Omnicell, Inc. breached its 50 day moving average in a Bearish Manner : OMCL-US : December 15, 2017
finance.yahoo.com - December 15 at 10:44 AM
Omnicell To Present At The 36th Annual J.P. Morgan Healthcare ConferenceOmnicell To Present At The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 14 at 5:09 PM
Omnicell (OMCL) Receives Buy Rating from Cantor FitzgeraldOmnicell (OMCL) Receives Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - December 14 at 12:34 AM
Omnicell's Rising Costs Affect Bottom Line Amid CompetitionOmnicell's Rising Costs Affect Bottom Line Amid Competition
finance.yahoo.com - December 11 at 4:49 PM
Omnicell, Inc. (OMCL) Given Consensus Recommendation of "Buy" by AnalystsOmnicell, Inc. (OMCL) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 11 at 1:58 PM
Omnicell (OMCL) Rating Reiterated by OppenheimerOmnicell (OMCL) Rating Reiterated by Oppenheimer
www.americanbankingnews.com - December 6 at 5:00 PM
Omnicell (OMCL) Earns Buy Rating from Cantor FitzgeraldOmnicell (OMCL) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - December 6 at 2:56 PM
Hacettepe University Oncology Hospital Introduces Omnicell i.v.STATION ONCO Robots to Chemotherapy UnitHacettepe University Oncology Hospital Introduces Omnicell i.v.STATION ONCO Robots to Chemotherapy Unit
finance.yahoo.com - December 6 at 10:32 AM
Omnicell’s (OMCL) Superior Earnings Growth Keep it a BuyOmnicell’s (OMCL) Superior Earnings Growth Keep it a Buy
investorplace.com - December 2 at 9:04 AM
Wolters Kluwer, Omnicell Partnership Delivers First Integrated IV Sterile Compounding Solution Covering the Full Quality Spectrum of Pharmacy Workflow and ComplianceWolters Kluwer, Omnicell Partnership Delivers First Integrated IV Sterile Compounding Solution Covering the Full Quality Spectrum of Pharmacy Workflow and Compliance
finance.yahoo.com - December 1 at 5:34 PM

SEC Filings

Omnicell (NASDAQ:OMCL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Omnicell (NASDAQ:OMCL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Omnicell (NASDAQ OMCL) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.